Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Halozyme has entered into a global collaboration and license agreement with Incyte to develop subcutaneous formulations of Incyte's drug INCA033989, a mutant calreticulin-targeted monoclonal antibody for myeloproliferative neoplasms, using Halozyme's ENHANZE® drug delivery technology. This partnership aims to enhance the delivery of Incyte's therapeutic candidate.